AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced management will participate in two upcoming investor conferences:
2026 Jefferies Global Healthcare Conference
1x1 Meetings: Tuesday, June 2
New York, NY
Evercore 2026 Emerging Private Biotech Conference
Ophthalmology Panel: Wednesday, June 24, 8:50 a.m. ET
Newport, RI
About Ollin Biosciences
Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.
Contacts
Media:
Katie Engleman
1AB
katie@1abmedia.com
